Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula

  title={Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula},
  author={Behrooz Kasraee and Parvin Mansouri and Susan Farshi},
  journal={Journal of Cosmetic Dermatology},
  pages={293 - 295}
L‐Cysteamine is a biological antioxidant produced during the coenzyme A metabolism cycle and is naturally present in all mammalian cells. The efficacy of topical cysteamine for the treatment of melasma has been recently shown in two double‐blind, randomized, and placebo‐controlled clinical trials. Herein, we report a 44‐year‐old patient with melasma resistant to Kligman's formula (Pigmanorm cream), who was successfully treated with topical cysteamine as a new depigmenting agent. Skin… 
10 Citations
Efficacy of topical cysteamine hydrochloride in treating melasma: a systematic review
A topical 5% cysteamine hydrochloride formulation, the structure of which is notably more stable and with a less foul odor than its prior counterparts, is assessed in the treatment of melasma.
Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman’s formula in subjects with epidermal melasma: A randomized, double‐blind clinical trial study
  • Maryam Karrabi, J. David, M. Sahebkar
  • Medicine
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging
  • 2020
This study was aimed at the evaluation of the effectiveness of Modified Kligman’s formula (MKF) in comparison with cysteamine 5% cream on the severity of epidermal melasma.
A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women
To assess the efficacy and safety of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women, a large number of women were enrolled in a double-blind, placebo-controlled study.
Resposta terapêutica da cisteamina no tratamento do melasma
The therapeutic response of cysteamine for the treatment of melasma is positive, reducing hyperpigmented lesions and with controllable adverse effects over the duration of treatment.
Novel Combination of a 650-Microsecond Neodymium-doped Yttrium Aluminium Garnet 1,064-nm Laser and Cysteamine Cream for the Treatment of Melasma: A Case Study.
This small case series suggests high levels of satisfaction can be achieved using this combined topical and laser approach to melasma treatment.
Systematic review of clinical studies assessing the needling for treatment of melasma: Focusing on efficacy, safety, and recurrence rate
Needling can be suggested as an effective and safe method with low recurrence rate for the treatment of melasma, so that the mean MASI score was significantly higher than those who used lightening serum alone.
The pathogenesis of melasma and implications for treatment
Melasma is a complex and poorly understood disorder, with high rates of treatment failure and recurrences, and its causes are poorly understood.
Estudo Prospectivo sobre a Cisteamina no Tratamento do Melasma
This estudo teve como objetivo realizar um levantamento de informacoes sobre patentes relacionadas ao uso da Cisteamina como um despigmentador da pele com melasma.
Estudo Prospectivo sobre a Cisteamina no Tratamento do Melasma
 O tratamento de melasma, desordem pigmentar caracterizada por manchas escuras na pele, é difícil e demorado, pois não há cura, apenas controle. Conforme os últimos estudos na área de dermatologia, a
  • Reactions Weekly
  • 2019


Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study
Cysteamine cream showed significant efficacy in decreasing melanin content of the lesions, as established by Dermacatch® as a new measuring method.
Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma.
In comparison to topical treatments, triamcinolone microinjection is a new, safe and strong therapeutic method for treatment of melasma.
Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review
An evidence-based review of interventions available for the treatment of melasma found topical depigmenting agents were found to be the most effective in treating moderate-to-severe melasma, with combination therapies, such as triple-combination therapy, yielding the best results.
Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double‐blind placebo‐controlled trial
Melasma is a difficult‐to‐treat hyperpigmentary disorder. While cysteamine is a known potent depigmenting agent, its efficacy in treating melasma has not been tested.
Melasma: Treatment strategy
Melasma, a hypermelanosis of the face, is a common skin problem of middle-aged women of all racial groups, especially with dark complexion, and genetic influences, exposure to sunlight, pregnancy, oral contraceptives, estrogen-progesterone therapies, thyroid dysfunction, cosmetics, and drugs have been proposed.
Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma
Glycolic acid has been added to hydroquinone formulations in the past to enhance their depigmentation effects, but may cause irritation, leading to postinflammatory hyperpigmentation.
Depigmentation of black guinea pig skin by topical application of cysteaminylphenol, cysteinylphenol, and related compounds.
Depigmentation of black skin by 4-S-CAP appeared to derive from a decreases in the number of functioning melanocytes; a decrease in theNumber of melanosomes synthesized within the melanocytes and transferred to keratinocytes; and destruction of the membranous organelles of the melanocyte.
A new formula for depigmenting human skin.
The formula was therapeutically effective in treatment of melasma, ephelides, and postinflammatory hyperpigmentation and Senile lentigines were resistant to this therapy.
Increased human dermal microvascular endothelial cell survival induced by cysteamine
Cysteamine concentrations, similar to those described in plasma of cystinosis patients, stimulate HDMVEC viability and proliferation and increase intracellular GSH content.